Trametinib dimethyl sulfoxide

LONDON, April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application (ANDA) for trametinib tablets from Novugen. Hikma also announces it has entered into a commercial agreement with Novugen where Hikma will be responsible for all US sales and marketing of this product, which Novugen will manufacture and supply to Hikma. Trametinib is an orally administered kinase inhibitor medication used to treat certain cancers. When launched, Hikma will have 180 days of US generic market sales exclusivity for this product. "Hikma's Generics business is accelerating its efforts to expand its pipeline by developing and acquiring important medicines in growing therapeutic areas most needed by US patients and healthcare providers," said Dr. Hafrun Fridriksdottir, president of Hikma Generics. "Our acquisition of this cancer treatment strengthens our broad US pipeline of essential medicines and will further our ability to put better health within reach every day for millions of Americans." "As cancer treatment remains a critical healthcare challenge, our partnership with Hikma reflects a shared commitment to ensuring the availability of effective, cost-efficient, and high-quality oncology treatments in the US," said Rahil Mahmood, Chief Executive Officer of Novugen. "This exclusive first-to-file molecule is a testament to Novugen's innovation, regulatory excellence, and dedication to expanding access to high-barrier, niche products with limited alternatives—ensuring life-changing treatments reach more US patients. With Hikma's strong market presence and commercial capabilities, this collaboration represents an excellent strategic synergy." According to IQVIA, US sales of trametinib, sold under the brand name Mekinist® (trametinib) Tablets, were approximately $436 million in the 12 months ending December 2024. Hikma's Generics business supplies a range of oral, inhalation and other generic and specialty products in the North American market, and has expertise in complex technologies, such as nasal sprays, where we are the largest supplier by volume in the US1. 1IQVIA MAT December 2024, volumes by eaches Mekinist® is a registered trademark of Novartis Pharma AG This product has been approved for marketing in the United States by the US FDA. This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States. Enquiries Hikma Pharmaceuticals PLC About Hikma (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: About Novugen Novugen is a wholly owned subsidiary of SciTech International, a UAE-based group with over 30 years of expertise in the healthcare industry. The company has successfully ventured into strategic healthcare businesses and developed world-class healthcare facilities worldwide. Driven by a passion for science and a bold global strategy, Novugen specializes in niche, difficult-to-formulate generics across various therapeutic areas, including general and oncology pharmaceuticals, while adhering to stringent global quality standards. With vertical integration from research and development to manufacturing in Malaysia, Novugen maintains full control over its supply chain. Its state-of-the-art manufacturing facilities, comply with USFDA, EMA, PIC/S, and WHO regulatory requirements. Novugen is also the first in Malaysia and the only in Southeast Asia with USFDA-approved pharmaceutical manufacturing facilities dedicated to oral solid dosage forms for general medicines and highly potent oncology drugs. This accreditation positions Novugen as the first in Malaysia to manufacture and export high-quality medicines for the U.S. market. Novugen is committed to expanding early access to complex pharmaceutical products that often lack robust generic alternatives. Through continuous innovation, we strive to lead the way in delivering high-quality, technology-driven pharmaceuticals globally. SOURCE Hikma Pharmaceuticals USA Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

诺华中国管理层迎来新的变动。昨天，诺华邮件宣布：现任诺华中国肿瘤治疗领域肺癌领域和实体瘤产品组合负责人徐薇，将于2025年5月1日起担任诺华中国眼科、移植及中枢神经治疗领域负责人，并将加入国际业务部中国管理团队。邮件内容大致如下：继上个月宣布国际业务部中国管理团队任命后，很高兴地向大家宣布后续的管理层任命，持续为我们才华横溢、充满热情的员工提供成长和发展的机会，践行诺华人才发展原则。非常高兴地宣布现任诺华中国肿瘤治疗领域肺癌领域和实体瘤产品组合负责人徐薇，将于2025年5月1日起担任诺华中国眼科、移植及中枢神经治疗领域负责人，并将加入国际业务部中国管理团队，直接向我汇报。她将带领中国眼科、移植及中枢神经治疗领域团队，推动业务发展，继续为中国患者带来高价值的创新药物和服务。徐薇的职业生涯始于2003年的诺华中国眼科治疗领域，并先后在多家跨国药企的多个治疗领域积累了丰富的行业知识和管理经验。在她目前担任的诺华中国肺癌领域和实体瘤产品组合岗位上，徐薇通过积极整合资源和赋能团队，驱动了泰菲乐和迈吉宁的高速增长，并领导了妥瑞达在中国的成功上市，树立了诺华在少见靶点治疗领域的领导者地位。此外，徐薇也曾担任诺华中国县域市场部和可善挺市场部负责人。在可善挺市场部期间，徐薇带领团队通过制定清晰的市场策略和开展创新的全方位服务患者的一体化项目，成功打造了可善挺市场领先的品牌口碑。徐薇在不同的岗位角色和复杂的环境变化中，始终保持初心坚定信念，带领团队专注执行，致力于践行我们的价值观和行为准则，以惠及更多的患者。在继任者宣布之前，徐薇将在过渡期间继续担任肺癌领域和实体瘤产品组合临时负责人。感谢王嘉在兼任眼科、移植及中枢神经治疗领域临时负责人期间所做出的贡献。请和我一起预祝徐薇在新的岗位上取得成功！李尧诺华公司中国区总裁兼董事总经理来源：罗湿兄点击 阅读原文 了解更多